Taysha Gene Therapies (TSHA) Misses Q1 EPS by 24c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q1 EPS of ($1.31), $0.24 worse than the analyst estimate of ($1.07).

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
• Middleby board approves spin-off of food processing unit Midera
• Morgan Stanley sees little room left in steel rally, cuts Cleveland-Cliffs rating